DT-Web

DB04942 - Tamibarotene


Identification
Name Tamibarotene
Accession Number DB04942
Type small molecule
Description Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 351.4388
Groups approved
Monoisotopic Weight 351.183443671
Pharmacology
Indication Investigated for use/treatment in leukemia (unspecified).
Mechanism of action Tamibarotene is a specific agonist for retinoic acid receptor alpha/beta with possible binding to retinoid X receptors (RXR).
Absorption Not Available
Protein binding Over 99%, predominantly to serum albumin.
Biotransformation Not Available
Route of elimination Not Available
Toxicity Not Available
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions Not Available
Food Interactions Not Available

Targets


Retinoic acid receptor alpha
Name Retinoic acid receptor alpha
Gene Name RARA
Pharmacological action yes
Actions agonist
References
  • Miwako I, Kagechika H: Tamibarotene. Drugs Today (Barc). 2007 Aug;43(8):563-8. - Pubmed
  • Sanda T, Kuwano T, Nakao S, Iida S, Ishida T, Komatsu H, Shudo K, Kuwano M, Ono M, Ueda R: Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis. Leukemia. 2005 Jun;19(6):901-9. - Pubmed
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
  • Jimi S, Mashima K, Matsumoto T, Hara S, Suzumiya J, Tamura K: RARalpha is a regulatory factor for Am-80-induced cell growth inhibition of hematologic malignant cells. Int J Oncol. 2007 Aug;31(2):397-404. - Pubmed
  • Tamibarotene: AM 80, retinobenzoic acid, Tamibaro. Drugs R D. 2004;5(6):359-62. - Pubmed
DTHybrid score 0.7252
Retinoic acid receptor beta
Name Retinoic acid receptor beta
Gene Name RARB
Pharmacological action yes
Actions agonist
References
  • Miwako I, Kagechika H: Tamibarotene. Drugs Today (Barc). 2007 Aug;43(8):563-8. - Pubmed
  • Sanda T, Kuwano T, Nakao S, Iida S, Ishida T, Komatsu H, Shudo K, Kuwano M, Ono M, Ueda R: Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis. Leukemia. 2005 Jun;19(6):901-9. - Pubmed
  • Jimi S, Mashima K, Matsumoto T, Hara S, Suzumiya J, Tamura K: RARalpha is a regulatory factor for Am-80-induced cell growth inhibition of hematologic malignant cells. Int J Oncol. 2007 Aug;31(2):397-404. - Pubmed
  • Tamibarotene: AM 80, retinobenzoic acid, Tamibaro. Drugs R D. 2004;5(6):359-62. - Pubmed
DTHybrid score 0.7248

Predictions


Id Partner name Gene Name Score
162 Retinoic acid receptor gamma-1 RARG 0.2416
88 Retinoic acid receptor RXR-beta RXRB 0.2216
780 Retinoic acid receptor RXR-gamma RXRG 0.1795
459 Retinoic acid receptor RXR-alpha RXRA 0.1545
5934 Cytochrome P450 26A1 CYP26A1 0.0862
564 Cellular retinoic acid-binding protein 1 CRABP1 0.085
331 Retinol-binding protein I, cellular RBP1 0.051
859 Cellular retinoic acid-binding protein 2 CRABP2 0.0389
4924 Cytochrome P450 2C8 CYP2C8 0.0328
3811 Cytochrome P450 19A1 CYP19A1 0.025
587 Serum albumin ALB 0.0197
4200 Cytochrome P450 1A2 CYP1A2 0.0156
1588 Multidrug resistance protein 1 ABCB1 0.015
↑